PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) axis have transformed the clinical management of patients with metastatic non‐small cell lung cancer (NSCLC) whose tumors bear no druggable oncogenic alteration.